- Previous Close
176.21 - Open
177.00 - Bid 182.94 x 800
- Ask 182.79 x 800
- Day's Range
171.80 - 186.11 - 52 Week Range
135.85 - 186.11 - Volume
7,834,168 - Avg. Volume
5,457,781 - Market Cap (intraday)
321.689B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
52.35 - EPS (TTM)
3.48 - Earnings Date Oct 25, 2024 - Oct 29, 2024
- Forward Dividend & Yield 6.20 (3.52%)
- Ex-Dividend Date Jul 15, 2024
- 1y Target Est
186.08
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
www.abbvie.com50,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ABBV
View More
Related Videos: ABBV
Performance Overview: ABBV
Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABBV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABBV
View MoreValuation Measures
Market Cap
321.69B
Enterprise Value
377.62B
Trailing P/E
60.93
Forward P/E
16.89
PEG Ratio (5yr expected)
0.50
Price/Sales (ttm)
5.87
Price/Book (mrq)
40.18
Enterprise Value/Revenue
6.87
Enterprise Value/EBITDA
41.30
Financial Highlights
Profitability and Income Statement
Profit Margin
11.02%
Return on Assets (ttm)
7.71%
Return on Equity (ttm)
56.24%
Revenue (ttm)
54.4B
Net Income Avi to Common (ttm)
5.95B
Diluted EPS (ttm)
3.48
Balance Sheet and Cash Flow
Total Cash (mrq)
18.07B
Total Debt/Equity (mrq)
924.06%
Levered Free Cash Flow (ttm)
23.61B
Research Analysis: ABBV
View MoreCompany Insights: ABBV
ABBV does not have Company Insights
Research Reports: ABBV
View MoreAbbVie's Next Generation Immunology Drugs Are Offsetting the Biosimilar Pressures to Humira
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
RatingPrice TargetHOLD on Humira competition
AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
RatingPrice TargetStocks are higher with small-caps again leading the way, up 1.5%.
Stocks are higher with small-caps again leading the way, up 1.5%. There's a lot of news driving market mood today - big bank earnings, inflation data on the wholesale side, and a re-pivot back to tech stocks after a selloff yesterday. Big banks are reporting good and bad new. Today's PPI data came in hotter than expected, with June up 2.6% compared to a year ago. On a monthly basis, prices kicked up 0.2% after being unchanged the month before. Today's inflation data comes a day after the very welcome news on the consumer side that CPI fell to 3.0% in June, more than expected. Wall Street will need to rest up this weekend as earnings, across a broad specter of sectors, really kick into gear next week. It's likely to be a long weekend for President Biden as the drum continues to beat for him to drop out of the presidential race.
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
RatingPrice Target